Oslo, Norway, June 14, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced that 100,000 share options have been granted to Katrine Husum in connection with her appointment as Director Project and Alliance Management. The share options will have a strike price of NOK 69.58 per share, vest in four equal tranches on February 1 each year and expire February 1, 2026. After the award of the share options, Katrine Husum holds a total of 100,000 share options and 0 shares.

Please see further details in attached document.